Cross-Crystal Averaging with Search Models to Improve Molecular Replacement Phases  by Li, Weikai & Li, Fang
Structure
Ways & MeansCross-Crystal Averaging with Search Models
to Improve Molecular Replacement Phases
Weikai Li1 and Fang Li2,*
1Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA
2Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
*Correspondence: lifang@umn.edu
DOI 10.1016/j.str.2010.12.007SUMMARY
The application of molecular replacement (MR) in
macromolecular crystallography can be limited by
the ‘‘modelbias’’problem.Hereweproposeastrategy
to reduce model bias when only part of a new struc-
ture is known: after theMR search, structure determi-
nationof theunknownpart of thenewstructure canbe
facilitated by cross-crystal averaging of the known
part of the new structure with the search model. This
strategy dramatically improves electron density in
the unknown part of the new structure. It has enabled
us to determine the structures of two coronavirus
receptor-binding domains each complexed with their
receptor atmoderate resolutions. In a test case, it also
enabled automated model building when >50% of an
antigen-antibody complex was absent. These results
suggest that this averaging strategy can be routinely
used after MR to enhance the interpretability of elec-
tron density associated with missing model.
INTRODUCTION
In X-ray crystallography, the phase problem must be solved to
determine macromolecular structures from diffraction data
(Drenth, 2007). Phases can be obtained using either experi-
mental methods or molecular replacement (MR) (Rossmann
and Blow, 1962). Unlike the experimental methods, MR does
not require experimentally determined phases for the unknown
structure; instead, it relies on the existence of an MR model,
a previously determined structure that either has homology to
or is part of the new structure. The MR search simulates the
packing of the MR model in the new crystal, and finds the best
match to the diffraction data. Afterward, theoretical phases of
the new structure can be calculated from the newly placed MR
model and combined with the diffraction data of the new
structure to calculate electron density maps. Compared with
the experimental methods, MR does not require any bench
work and hence is quicker and more convenient. Given the
ever-expanding database of known structures that can serve
as MR models and recent development in homology modeling
(Marti-Renom et al., 2000; Qian et al., 2007), MR is bound to
play an increasingly important role in future macromolecular
crystallography.
Despite theaboveadvantages andpromises, the applicationof
MR in macromolecular crystallography has been hampered byStructure 19, 15the ‘‘model bias’’ problem (Hodel et al., 1992). Model bias occurs
due to the fact that phases usually contain more structural
information than diffraction intensity and hence model-based
phases yield electron density maps with heavy bias toward
features of the MR model. Therefore, as a problem intrinsically
associated with MR, model bias often leads to misinterpretation
of electron densitymaps in the part representedby theMRmodel
and/or un-interpretability of electron density maps in the part not
represented by theMRmodel. Many strategies have been devel-
oped to reduce model bias in electron density map calculations.
Notable approaches include the SIGMAA estimation of model
phases (Read, 1997), calculation of composite omit maps (Hodel
et al., 1992), density-modification methods with desirable phase
combinations (Cowtan, 1999), and a prime-and-switch method
(Terwilliger, 2004). However, these strategies are useful only
when a major fraction of the new structure is represented by the
MR model. If a significant portion of the new structure is not rep-
resented by the MR model, the partial phases generated by the
MR model are usually insufficient to generate interpretable elec-
tron density maps in the unknown part.
Here we show that if part of a new structure is known and
solved by MR, cross-crystal averaging between the MR model
and the known part of the new structure can dramatically
improve the partial model phases, reduce model bias, and facil-
itate structure determination of the unknown part. We have
further developed a density/sigma ratio as a local real-space
indicator to monitor the improvement of the electron density
maps during the averaging process. We have successfully
used this strategy to determine two new structures as well as
a representative structure of an antibody-antigen complex.RESULTS
General Strategy
In this study we focus on structure determination of macromole-
cules ormacromolecular complexeswhose partial structures are
known. These cases are common in macromolecular crystallog-
raphy; they can be protein-protein complexes, protein-nucleic
acid complexes, or multi-domain macromolecules where the
structures of one or several components are known. As a general
procedure, we take the following steps:
1. Obtain the structure and diffraction data of the MR model
from the Protein Databank (PDB).
2. Carry out MR search in the new crystal using the MR
model. Once the MR solution has been found, perform
rigid-body refinement of the newly placed MR model
against the diffraction data of the new structure. Calculate5–161, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 155
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new structure.
3. Performcross-crystal averaging,with thenewlyplacedMR
model in the new crystal as the referencemolecule and the
MR model in its original crystal as the target molecule.
Before averaging, amolecularmaskneeds tobegenerated
for the reference molecule, and rotation and translation
matrices need to be calculated to match the reference
molecule to the target molecule. If there is any large-scale
domain movement in the reference molecule compared
with the target molecule, separate masks need to be
generated for each of the domains. If noncrystallographic
symmetry (NCS) exists in the new crystal, NCS averaging
can be carried out at the same time as the cross-crystal
averaging. After a separate mask is generated to cover
the unknown part of the new structure, the unknown part
of the new structure is subjected to NCS averaging,
whereas the known part of the new structure is subjected
to both NCS averaging and cross-crystal averaging.
4. After averaging, a new electron density map is calculated
from observed structure amplitudes and phases derived
from Fourier back-transforming the previous modified
map. Based on the new electron density map, the molec-
ular masks and averaging matrices are updated.
5. Repeat steps 3 and 4, until the electron density map in the
unknown part of the new structure is interpretable and
model building can be carried out.
Density/Sigma Ratio as a Real-Space Indictor
of Electron Density Maps
To investigate how the averaging process works, we introduce
here a new real-space indicator, the density to sigma ratio
(r/s), to monitor the improvement of the electron density maps
in the unknown part of the new structure:
r=s =
 X
atoms
X
r
Dr;atom
!
= ðN  sÞ:
Here, r is the averaged electron density around each atomof the
final refined structural model, s is the noise of the whole electron
density map (determined as the standard deviation of the electron
density),
P
atoms
P
r Dr;atom is the sum of the electron density of
asphereofgridpointsaroundeachatomof themodel, r is the radius
of the sphere, and N is the total number of atoms of the model.
Unlike other real space indicators such as map correlation or
reciprocal space indicators such as figure ofmerit, r/smeasures
the signal/noise ratio of any specific region on an electron
density map and thus is directly associated with the interpret-
ability of the electron density map. Like map correlation, r/s
can be calculated after the structure is determined in the previ-
ously unknown region, and thus is a useful real-space monitor
for investigating how electron density maps can be improved
by computational or experimental methods.
Structure Determination of SARS Coronavirus
Receptor-Binding Domain Complexed with Its Human
Receptor
Using the procedure described above, we have successfully
determined the crystal structure of SARS coronavirus156 Structure 19, 155–161, February 9, 2011 ª2011 Elsevier Ltd All rreceptor-binding domain (scRBD) complexed with its human
receptor angiotensin-converting enzyme 2 (ACE2) (Li et al.,
2005) (Figure 1). The mass of the ACE2 region was 70% of
the total mass of the ACE2-scRBD complex. Two different
ACE2 structures were available, in which the two lobes of
ACE2 adopt open and closed conformations, respectively
(Towler et al., 2004). We used the ACE2 structure in the open
conformation as the MR model, and found two ACE2 molecules
in each asymmetric unit (ASU) of the ACE2-scRBD complex
structure. The newly placed ACE2 in the ACE2-scRBD complex
structure was subjected to rigid-body refinement, with each of
the two lobes as a rigid body. The Rwork and Rfree after rigid-
body refinement were 41.7% and 43.2%, respectively. As
expected, the partial model phases generated from the newly
placed MR model were heavily biased toward ACE2, and the
resulting electron density map in the scRBD region was poor
and not interpretable (Figure 2A). A 2-fold NCS averaging in
both the ACE2 region and scRBD region did not yield interpret-
able electron density map either (Figure 2B).
To improve the partial model phases of the ACE2-scRBD
complex structure, we carried out cross-crystal averaging
between the ACE2 region in the ACE2-scRBD complex structure
and the ACE2 structure in the open conformation. At the same
time, we also performed a 2-fold NCS averaging in both the
ACE2 region and scRBD region in the ACE2-scRBD complex
structure. Two masks were generated for each of the two lobes
of ACE2 based on the newly placed MR model, and one mask
was generated to generously cover the estimated region of
scRBD (Figure 1). After averaging, the electron density map
calculated from the new phases showed significantly improved
features in the scRBD region. Based on the new electron density
map, both the averaging matrices and masks were updated and
another round of averaging was performed. After the second
round of averaging, the electron density map was clearly inter-
pretable in the scRBD region (Figure 2C), and hence the model
was built for the scRBD region. The structure of ACE2-scRBD
complex was refined at 2.9 A˚ to Rwork 22.1% (Rfree 27.5%).
Using r/s in the scRBD region as a real-space indicator, we
were able to evaluate the effectiveness of cross-crystal aver-
aging plus NCS averaging in the improvement of the electron
density maps (Figure 2D). NCS averaging only improved r/s
in the scRBD region from 0.8 to 1.2, which was still insufficient
for model building; the cross-crystal averaging plus NCS aver-
aging, however, improved r/s in the scRBD region from 0.8 to
1.8, which led to efficient model building. The averaging did not
significantly improve r/s in the ACE2 region (r/s was 2.6 and
2.7 before and after averaging, respectively), likely because
the structural differences between the model and the ACE2
region in the complex were small and hence the electron
density in the ACE2 region was dominated by the contribution
from the model. Moreover, during the averaging process,
whether or not cutting the resolution of the model (2.2 A˚) to
the same as that of the complex (2.9 A˚) has little impact on
the final r/s in the scRBD region, and thus dampening B factor
was not applied to the model crystal data. The above analyses
using r/s as indicators were consistent with visual inspections
of the electron density maps. As a comparison, the map
correlation coefficients were also calculated, showing the
improvement of the electron density maps after averagingights reserved
Figure 1. Scheme of Cross-Crystal Aver-
aging to Determine the Structure of SARS
Coronavirus Receptor-Binding Domain
Complexed with Human ACE2
The masks covering the two lobes of the ACE2 in
the reference molecule (scRBD-ACE2 complex)
are shown in red and blue, respectively. The
matrices that move the reference molecule to
the NCS-related molecule and the molecules in
the second crystal are indicated by arrows. An
additional mask is generated to generously cover
the missing scRBD domain in the reference mole-
cule. The boundary of this mask is also drawn in
dashed lines in the NCS related molecule.
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An Averaging Method for Molecular Replacement(Figure 2E). In addition, after the first cycle, the map after NCS
averaging plus cross-crystal averaging and the map after NCS
averaging alone have a phase difference of 32.2.StructureDetermination of NL63Coronavirus Receptor-
Binding Domain Complexed with Its Human Receptor
Using the same averaging strategy, we have also successfully
determined the crystal structure of NL63 coronavirus receptor-
binding domain (nlRBD) complexed with human ACE2 (Wu
et al., 2009), the common receptor protein for both SARS coro-
navirus and NL63 coronavirus. Themass of the ACE2 region was
75% of the total mass of the ACE2-nlRBD complex. The nlRBD
and scRBD have no sequence homology, and MR search using
the scRBD structure as the MR model did not find any solution.
Instead, we carried out anMR search using the ACE2 structure in
the open conformation as the MR model. We found four ACE2
molecules in each ASU of the new crystal. Rwork and Rfree after
rigid-body refinement were 45.7% and 46.8%, respectively.
The resulting election-density map was not interpretable in the
nlRBD region (Figure 3A). A 4-fold NCS averaging in both the
ACE2 region and nlRBD region improved the electron density
map in the nlRBD region, which was still insufficient for model
building (Figure 3B).
We carried out cross-crystal averaging in the ACE2 region
between the ACE2-nlRBD complex structure and the ACE2
structure in the open conformation. At the same time, we also
performed a 4-fold NCS averaging in both the ACE2 region
and nlRBD region in the ACE2-nlRBD complex structure. After
the averaging, the electron density map in the nlRBD region
was clearly interpretable (Figure 3C). Both r/s and map correla-
tion coefficients were improved after the averaging (Figures 3D
and 3E). We built the nlRBD model and refined the structure at
3.3 A˚ to Rwork 27.6% (Rfree 30.8%). It turned out that the nlRBDStructure 19, 155–161, February 9, 2011and scRBD have no structural homology
to each other, but bind to a common
region on ACE2.
Structure Analysis of HIV-1 gp120
Envelope Glycoprotein Complexed
with Its Receptor CD2
and Antibody 17b
To further test the effectiveness of cross-
crystal averaging in structure determina-tion of macromolecular complexes, we selected one representa-
tive structure from the PDB, HIV-1 gp120 envelope glycoprotein
complexed with its receptor CD4 and antibody 17b (Zhou et al.,
2007). Although in the original publication the structures of
gp120, CD4 and antibody 17b were all previously known, in
this study we only used antibody 17b as the MR model and
monitored the electron density maps in the gp120-CD4 regions.
Notably, the mass of the antibody was46%of the total mass of
the complex and there was no NCS in the crystal. Rigid-body
refinement of the initial MR solution at 2.2 A˚ gave Rwork and Rfree
of 48.4% and 50.0%, respectively. Not surprisingly, the resulting
election-density map was not interpretable in the gp120-CD4
regions (Figure 4A). We carried out cross-crystal averaging in
the antibody region between the gp120-CD4-antibody complex
structure and the antibody apo-structure. Because of the confor-
mational flexibility of the antibody, we used four masks to cover
each of the two domains in the light chain and heavy chain. After
averaging, the electron density map in the gp120-CD4 region
was clearly interpretable (Figure 4B). The significantly improved
map even allowed automated building of the gp120-CD4 model,
with most of the backbone correctly traced (Figure 4C). Both r/s
and map correlation coefficients were improved after the aver-
aging (Figures 4D and 4E).
DISCUSSION
In this study, we have developed a strategy to reduce the model
bias problem associated with partial molecular replacement
(MR) model phases. Because of model bias, the partial MR
model phases are often insufficient for structure determinations
of the parts of a new crystal that are not represented by the MR
model. In these cases, experimental phases are usually sought
to complement the partial MR model phases, a tedious andª2011 Elsevier Ltd All rights reserved 157
Figure 2. Cross-Crystal Averaging in the ACE2 Region Improves Electron Density Map in the scRBD Region in the scRBD-ACE2
Complex Crystal
(A) Part of the electron density map in the scRBD region after rigid-body refinement and before averaging.
(B) The same region after NCS averaging.
(C) The same region after cross-crystal and NCS averaging.
(D) Changes of r/s in the scRBD region during different averaging processes.
(E) Changes of the map correlation coefficients in the scRBD region during different averaging processes.
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show that after the MR search, the MR model should not be dis-
carded as in common practice; instead, it can be further used as
a cross-crystal averaging target with the known part of the new
structure to improve the partial MR model phases. We suggest
that this averaging strategy should be routinely used after MR,
and thereby enable certain macromolecular structures contain-
ing significant portions of unknown structures to be determined
without the necessity for experimental phases.
We have successfully applied this averaging strategy in deter-
mination of macromolecular structures. This strategy has
enabled us to determine two new crystal structures, SARS coro-
navirus RBD and NL63 coronavirus RBD, each complexed with
their common receptor ACE2. The RBD regions where the struc-
tures were previously unknown occupy 30% and 25% of the
total masses of the complexes, respectively. Yet, the cross-
crystal averaging strategy, aided by NCS averaging, led to inter-
pretable electron density maps at moderate resolutions. This
averaging strategy has been further tested on a representative
structure selected from the PDB, the HIV-1 gp120 complexed
with its receptor CD4 and antibody 17b. The gp120-CD4 regions
whose structures were not used in the MR search step occupy
54%of the total mass of the complex. Remarkably, cross-crystal
averaging in the antibody region, without the aid of NCS aver-
aging, led to interpretable electron density maps in the gp120-
CD4 region that allowed automated model building. Our study158 Structure 19, 155–161, February 9, 2011 ª2011 Elsevier Ltd All rsuggests that many antibody-antigen complex structures may
be determined using this averaging strategy. In this sense, the
averaging strategy is particularly significant, given the preva-
lence of antibody-antigen complex crystals.
To track the effect that the averaging strategy has on electron
density, we have introduced a new real-space indicator, r/s, to
measure the signal/noise ratio of electron density maps. The r/s
indicator allows us to directly follow the improvement of the elec-
tron density maps during the averaging process. It confirms that
cross-crystal averaging significantly improves the quality of elec-
tron density maps in the region where the structure was previ-
ously unknown. Because this region is not represented by the
MR model, improvement of the electron density maps in this
region means that model bias has been reduced. Why is the
averaging strategy so effective in reducing model bias and
improving electron densities in the unknown part of the new
structure? This is because this method effectively brings in
new, independent experimental data for the known part of the
new structure, through independent Fourier transformation of
this part in another crystal form containing the model. Therefore,
although this method does not significantly improve the electron
density in the known part of the new structure due to the good
match of this region in the two crystal forms, the inclusion of
the new data for the known part of the new structure reduces
the relative contribution of the unknown part in the combined
data. This results in higher signal/noise ratio and more accurateights reserved
Figure 3. Cross-Crystal Averaging in the ACE2 Region Improves Electron Density Map in the NL63 Coronavirus Receptor-Binding Domain
Region in the nlRBD-ACE2 Complex Crystal
(A) Part of the electron density map in the nlRBD region after rigid-body refinement and before averaging.
(B) The same region after NCS averaging.
(C) The same region after cross-crystal and NCS averaging.
(D) Changes of r/s in the nlRBD region during different averaging processes.
(E) Changes of the map correlation coefficients in the nlRBD region during different averaging processes.
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An Averaging Method for Molecular Replacementphase probabilities, which subsequently improve the quality of
the electron density in the unknown portion.
This averaging strategy has potential broad applications in
macromolecular crystallography. As the recognition that many
macromolecules function as part of complexes, the desire to
solve crystal structures of biologically important macromolecular
complexes is growing. The averaging strategy described in this
study can facilitate structure determinations of these large
macromolecules and macromolecular complexes when parts
of their structures are known. How well the averaging strategy
works may depend on a number of factors. It may work more
effectively when high resolution and high quality data are avail-
able, when NCS is existent, when the known part is large relative
to the unknown part in the new structure, andwhen the structural
differences between the known part of the new structure and the
model are small or the sequence homology between them is
high. Because these factors interplay with each other, the limits
of these factors are impossible for one study to explore, but
hopefully will be established by further application of the tech-
nique in future studies. Despite the potential broad applications
discussed above, the averaging strategy has some limitations.
Although it can effectively reduce model bias in the unknown
part of a new structure, this strategy is still subjected to model
bias in the known part of the new structure. Consequently, it
may not improve the electron density map in the known part of
the new structure as effectively as it does in the unknown partStructure 19, 15of the new structure, especially when the structural differences
between the known part of the new structure and the model
are large or sequence homology between them is low. Neverthe-
less, because of its efficiency in reducing model bias in the
unknown parts of new structures as well as its potential general
applications in structure determinations of large macromole-
cules and macromolecular complexes, this averaging strategy
may help extend the utility of MR in macromolecular
crystallography.EXPERIMENTAL PROCEDURES
MR search was carried out using program PHASER (McCoy et al., 2007).
Cross-crystal averaging was performed using program DMMULTI (Cowtan,
1994). Molecular masks were generated and treated using programs
NCSMASK and MAPMASK installed in the CCP4 suite (Cowtan, 1994), and
MAPMAN and MAMA installed in the UPPSALA software factory (Kleywegt
and Jones, 1999). Rotation and translation matrices that match the reference
molecule to the target molecule were calculated using program PDBSET
(Bailey, 1994). Manual model building was carried out using programs O and
COOT (Emsley et al., 2010). Automatic model building was performed using
program BUCCANEER (Cowtan, 1994). Structure refinement was performed
using programs CNS (Brunger et al., 1998) and REFMAC (Murshudov et al.,
1997). Both the r and s of the r/s indicator were calculated using program
MAPMAN Peek (Kleywegt and Jones, 1999), with a radius of 1.1 A˚ for density
integration. Map correlation coefficients were calculated using program
OVERLAPMAP (Jones and Stuart, 1991). Phase differences were calculated
using program PHISTATS (Cowtan, 1994). PDB IDs: 1R42 for ACE2 in the5–161, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 159
Figure 4. Cross-Crystal Averaging in the Antibody Region Improves Electron Density Map in the gp120-CD4 Region in the gp120-CD4-
Antibody Complex Crystal
(A) Part of the electron density map in the gp120 region after rigid-body refinement and before averaging.
(B) The same region after cross-crystal averaging.
(C) Automated model building of the entire gp120 and CD4 domains based on the averaged map. The final models of the gp120 and CD4 are shown in blue, and
the automatically built skeleton is shown in red.
(D) Changes of r/s in the gp120-CD4 region during the averaging process.
(E) Changes of the map correlation coefficients in the gp120-CD4 region during the averaging process.
Structure
An Averaging Method for Molecular Replacementopen conformation, 2AJF for ACE2-scRBD complex, 3KBH for ACE2-nlRBD
complex, 2NY0 for gp120-CD4-antibody complex, and 1RZ8 for antibody
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